ESR1 and prostate cancer: Whereas in prostate cancer [196,197] and in basal breast cancer [115] the Orai3–Orai1 ratio was decreased, it was increased in another prostate cancer study [38], in estrogen receptor-positive breast cancer [65,115,198] and in non-basal breast cancer [115].